JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com - RBC Capital lowered its price target on Acadia Healthcare (NASDAQ:ACHC) to $28.00 from $43.00 on Wednesday, while maintaining an Outperform rating on the stock. The move comes as the healthcare provider’s shares have declined over 72% in the past year, with particularly steep losses of 51% in the last six months.
The price target reduction follows Acadia Healthcare’s second-quarter 2025 results released on August 5, which prompted RBC Capital to update its financial model for the company.
RBC Capital identified weaker Medicaid volume as the primary factor behind Acadia Healthcare’s revised outlook for 2025.
Despite the significant reduction in price target, RBC Capital analyst Ben Hendrix maintained an Outperform rating on Acadia Healthcare shares.
The updated $28 price target represents a 34.9% decrease from the previous target of $43 set by the investment firm.
In other recent news, Acadia Healthcare reported its second-quarter earnings for 2025, surpassing analyst expectations with an earnings per share (EPS) of $0.83, compared to the forecasted $0.70. This positive earnings surprise represents an 18.57% increase over projections. However, UBS lowered its price target for Acadia Healthcare to $31, citing deteriorating conditions and adjusting its 2025 EBITDA estimate to $687 million from a previous $705 million. Guggenheim also reduced its price target for the company to $29 due to concerns over weak Medicaid volume growth, which is expected to continue affecting earnings through the second half of 2025. Despite maintaining a Buy rating, Guggenheim highlighted that this trend could create a $30 million or 4% drag on yearly earnings. These recent developments reflect ongoing challenges for Acadia Healthcare in the current operating environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.